Baxter (NYSE:BAX) and Miromatrix Medical (Nasdaq:MIRO) today announced a collaborative research agreement on acute liver failure (ALF) treatments. As part of the collaboration, Eden Prairie, Minnesota-based Miromatrix created a new liver therapy. The therapy, called MiroLiverELAP, combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system. Miromatrix designed the MiroLiverELAP to provide external support to […]
Miromatrix Medical Inc.
MiroMatrix raises $23m for decellularizing tech
Decellularization technology developer MiroMatrix Medical raised $23 million in a new round of equity financing, according to an SEC filing posted last week. MiroMatrix develops and utilizes a proprietary technology to remove cells, or decellularize, organs and tissue. Currently, MiroMatrix has 510(k) clearance for its MiroMesh biological mesh used during hernia repair procedures and as a […]
Is Boston Scientific in line for a private equity takeover? | Wall Street Beat
Billionaire hedge fund manager David Tepper, of Appaloosa Management, bought 7.8 million shares of Boston Scientific stock during the 4th quarter, according to regulatory filings, for a stake with a market value of $41.6 million as of Dec. 31.
Voice-command health IT firm launches with $650,000 | Funding roundup
A group of Cincinnati gastroenterologists have been joined by several business and technology partners to launch a health IT company that develops intraoperative voice-command software to document surgical procedures.
The company, eMerge Health Solutions, received $650,000 in investment commitments, including $250,000 from state-supported venture development group CincyTech.
UMinn spinoff kicks founder off board | Personnel moves
Founders of companies often clash with CEOs hired to operate the business. But at Miromatrix Medical Inc., a regenerative medicine firm spun out of the University of Minnesota, it happened just over a year after the company began operations.
The company was spun out of UMinn in December 2009 and formally set up in February 2010 when the university signed an exclusive licensing agreement allowing the research of Doris Taylor to be commercialized.
